References
- Connor HE, DT Beattie. Naratriptan – pharmacology. In: Diener HC, ed. Drug Treatment of Migraine and Other Headaches. Monographs in Clinical Neuroscience. Basel: Karger, 2000: 124–33
- Saxena R, Tfelt Hansen P Triptans, 5-HT1B/1D receptor agonists in the acute treatment of migraine. In: Olesen J, Tfelt-Hansen T, Welch KMA, eds. The Headaches, 2nd edn. Philadelphia: Lippincott Williams & Wilkins, 2000:411–38
- Goadsby PJ Treatment of acute migraine attacks with naratriptan. In: Diener HC, ed. Drug Treatment of Migraine and Other Headaches. Monographs in Clinical Neuroscience. Basel: Karger, 2000:134–40
- Klassen A, Elkind A, Asgharnejad M, et al., on behalf of The Naratriptan S2WA3001 Study Group. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Headache 1997;37: 640–5
- Matthew NT, Asgharnejad M, Peykamian M, Laurenza A, on behalf of The Naratriptan S2WA3003 Study Group. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, cross-over study. The Naratriptan S2WA3003 Study Group. Neurology 1997;49: 1485–90
- Havanka H, Dahlöf C, Pop PH, et al. Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 Study Group. Clin Ther 2000;22:970–80
- Dahlöf C, Winter P, Whitehouse H, Hassani H. Randomized, double-blind, placebo-controlled comparison of oral naratriptan and oral sumatriptan in the acute treatment of migraine. Neurology 1997;48\(Suppl 3):A85–A86
- Gobel H, Winter P, Boswell D, et al. Comparison of naratriptan and sumatriptan in recurrence-prone migraine patients. Naratriptan International Recurrence Study Group. Clin Ther 2000;22:981–9
- Heywood J, Bomhof MAM, Pradalier A, et al., on behalf of the Naratriptan Long-Term Study Group. Tolerability and efficacy of naratriptan tablets in the acute treatment of migraine attacks for 1 year. Cephalalgia, 2000;20: 470–4